Schlierf G, Fischer H, Roche A, Stiehl A, Oster P, Schellenberg B, Vollmar J
MMW Munch Med Wochenschr. 1980 Feb 1;122(5):165-8.
The effect of bezafibrate (3 x 200 mg/day) on biliary lipids was studied in 12 healthy male subjects and in 13 patients with hyperlipidemias. In normal subjects, the lithogenic index, with bezafibrate and placebo administered in a double blind cross-over design, was 1.1 and 0.77 respectively. The difference was not significant. In patients, who have been treated with bezafibrate for 6 months to 3 years the index was 0.76, and 0.64 six weeks after discontinuation of the drug. This difference, too, was not significant. It appears, therefore, that contrary to findings with clofibrate, bezafibrate may not be associated with an increased risk of cholelithiasis. This question, however, can ultimately be answered with certainty only on the basis of long-time epidemiologic evidence.
在12名健康男性受试者和13名高脂血症患者中研究了苯扎贝特（3×200毫克/天）对胆汁脂质的影响。在正常受试者中，采用双盲交叉设计分别给予苯扎贝特和安慰剂时，成石指数分别为1.1和0.77。差异不显著。在接受苯扎贝特治疗6个月至3年的患者中，该指数为0.76，停药六周后为0.64。这一差异也不显著。因此，似乎与氯贝丁酯的研究结果相反，苯扎贝特可能与胆结石风险增加无关。然而，这个问题最终只有基于长期的流行病学证据才能得到确切答案。
